
Thomas Prebet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5684798/publications.pdf Version: 2024-02-01



THOMAS PREFT

#	Article	lF	CITATIONS
1	Mutations of polycombâ€associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia. British Journal of Haematology, 2009, 145, 788-800.	2.5	537
2	Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure. Journal of Clinical Oncology, 2011, 29, 3322-3327.	1.6	421
3	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood, 2016, 128, 253-264.	1.4	320
4	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 721-749.	4.9	314
5	A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood, 2012, 120, 4317-4323.	1.4	247
6	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Journal of Clinical Oncology, 2014, 32, 1242-1248.	1.6	227
7	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood, 2012, 119, 3211-3218.	1.4	220
8	NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 16-27.	4.9	170
9	BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood, 2013, 122, 3169-3177.	1.4	169
10	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood, 2009, 113, 3947-3952.	1.4	158
11	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. Journal of Clinical Oncology, 2009, 27, 4747-4753.	1.6	123
12	Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 923-932.	5.2	114
13	A new Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: a GOELAMS study. Leukemia, 2011, 25, 939-944.	7.2	101
14	The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Advances, 2018, 2, 1765-1772.	5.2	100
15	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology,the, 2018, 5, e63-e72.	4.6	95
16	Protein tyrosine kinase 7 has a conserved role in Wnt/βâ€catenin canonical signalling. EMBO Reports, 2011, 12, 43-49.	4.5	93
17	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i> -internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020. 105. 1507-1516.	3.5	91
18	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Advances, 2020, 4, 2866-2870.	5.2	81

#	Article	IF	CITATIONS
19	The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood, 2010, 116, 2315-2323.	1.4	79
20	Epigenetics in Cancer: A Hematological Perspective. PLoS Genetics, 2016, 12, e1006193.	3.5	77
21	Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Frontiers in Immunology, 2014, 5, 122.	4.8	75
22	Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia. Oncotarget, 2016, 7, 32532-32542.	1.8	75
23	The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplantation, 2012, 47, 639-645.	2.4	73
24	Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood, 2011, 117, 6650-6659.	1.4	72
25	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Leukemia, 2012, 26, 662-674.	7.2	72
26	Role of <i>ASXL1</i> and <i>TP53</i> mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget, 2015, 6, 8388-8396.	1.8	69
27	Incidence of 17p deletions and <i>TP53</i> mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes and Cancer, 2012, 51, 1086-1092.	2.8	67
28	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. Blood, 2013, 122, 2286-2288.	1.4	67
29	Azacitidine for the treatment of relapsed and refractory AML in older patients. Leukemia Research, 2015, 39, 124-130.	0.8	63
30	Azacitidine with or without Entinostat for the treatment of therapyâ€related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology, 2016, 172, 384-391.	2.5	63
31	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood, 2014, 124, 1312-1319.	1.4	61
32	Comparative clinical effectiveness of azacitidine <i>versus</i> decitabine in older patients with myelodysplastic syndromes. British Journal of Haematology, 2016, 175, 829-840.	2.5	59
33	Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société FranÁ§aise de Greffe de Moelle et de Thérapie Cellulaire. Experimental Hematology, 2008, 36, 535-544.	0.4	58
34	Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). Oncotarget, 2014, 5, 3168-3172.	1.8	58
35	A randomized phase II trial of azacitidine +/- epoetin-Â in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica, 2016, 101, 918-925.	3.5	55
36	Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings. Leukemia and Lymphoma, 2017, 58, 1022-1036.	1.3	53

#	Article	IF	CITATIONS
37	A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia, 2013, 27, 1479-1486.	7.2	50
38	Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. British Journal of Haematology, 2012, 157, 764-766.	2.5	49
39	Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia, 2021, 35, 2182-2198.	7.2	46
40	Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2016, 25, 307-317.	4.1	45
41	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Advances, 2019, 3, 1540-1545.	5.2	44
42	Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia. Leukemia and Lymphoma, 2013, 54, 1228-1234.	1.3	43
43	Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. PLoS ONE, 2015, 10, e0123768.	2.5	43
44	Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica, 2015, 100, 780-785.	3.5	42
45	A phase 1 study of the panâ€bromodomain and extraterminal inhibitor mivebresib (ABBVâ€075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 2943-2953.	4.1	42
46	Reduced-intensity conditioning with Fludarabin, oral Busulfan, and thymoglobulin allows long-term disease control and low transplant-related mortality in patients with hematological malignancies. Experimental Hematology, 2010, 38, 1241-1250.	0.4	36
47	PICALM–MLLT10 acute myeloid leukemia: A French cohort of 18 patients. Leukemia Research, 2012, 36, 1365-1369.	0.8	36
48	Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia. American Journal of Hematology, 2014, 89, 604-609.	4.1	36
49	Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opinion on Investigational Drugs, 2011, 20, 287-295.	4.1	35
50	PTK7: A cell polarity receptor with multiple facets. Cell Cycle, 2011, 10, 1233-1236.	2.6	32
51	Lenalidomide in lowerâ€risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesisâ€stimulating agents. British Journal of Haematology, 2012, 156, 619-625.	2.5	32
52	Comparison of the prognostic utility of the revised International Prognostic Scoring System and the <scp>F</scp> rench Prognostic Scoring System in azacitidineâ€ŧreated patients with myelodysplastic syndromes. British Journal of Haematology, 2014, 166, 352-359.	2.5	31
53	Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia, 2010, 24, 467-469.	7.2	29
54	Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure. Haematologica, 2013, 98, e18-e19.	3.5	29

#	Article	IF	CITATIONS
55	FES kinases are required for oncogenic FLT3 signaling. Leukemia, 2010, 24, 721-728.	7.2	28
56	Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations. Leukemia Research, 2014, 38, 1381-1391.	0.8	27
57	Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised <scp>IPSS</scp> . British Journal of Haematology, 2014. 167. 62-68.	2.5	27
58	Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia. Haematologica, 2014, 99, e185-e187.	3.5	27
59	Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia. Blood Advances, 2018, 2, 2063-2071.	5.2	26
60	Concomitant germâ€line <i><scp>RUNX</scp>1</i> and acquired <i><scp>ASXL</scp>1</i> mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279.	2.2	25
61	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology, 2018, 9, 977.	4.8	25
62	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). Blood, 2016, 128, 215-215.	1.4	25
63	Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110–FGFR1 fusion: Report of a new case and review of the literature. Leukemia Research, 2008, 32, 1304-1308.	0.8	24
64	Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation, 2010, 45, 165-170.	2.4	24
65	Impact of Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation on Women's Fertility. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 704-710.	0.4	24
66	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term <i>Ex Vivo</i> Culture Informs Outcomes in Acute Myeloid Leukemia Patients. Cancer Research, 2016, 76, 2082-2086.	0.9	24
67	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. Blood, 2014, 124, 3251-3251.	1.4	23
68	Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the <i>Groupe Francophone Des Myélodysplasies</i> . Haematologica, 2017, 102, 728-735.	3.5	22
69	<i>NPM1</i> mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents. Haematologica, 2018, 103, e455-e457.	3.5	22
70	Tumor cell contamination in ovarian tissue cryopreserved before gonadotoxic treatment: should we systematically exclude ovarian autograft in a cancer survivor?. Bone Marrow Transplantation, 2010, 45, 1247-1248.	2.4	21
71	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2015, 5, e292-e292.	6.2	21
72	A phase 1 dose-escalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL) Journal of Clinical Oncology, 2015, 33, 3065-3065.	1.6	21

#	Article	IF	CITATIONS
73	Planctomycetes DNA in Febrile Aplastic Patients with Leukemia, Rash, Diarrhea, and Micronodular Pneumonia. Journal of Clinical Microbiology, 2014, 52, 3453-3455.	3.9	20
74	Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia. Leukemia Research, 2020, 91, 106339.	0.8	20
75	Improved outcome of patients with low―and intermediateâ€risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine. Cancer, 2011, 117, 974-981.	4.1	19
76	Comparison of 60 or 90 mg/m ² of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics. American Journal of Hematology, 2015, 90, E29-30.	4.1	19
77	Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion, 2017, 57, 289-295.	1.6	19
78	Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study. International Journal of Molecular Sciences, 2017, 18, 837.	4.1	19
79	Emerging treatment options for patients with high-risk myelodysplastic syndrome. Therapeutic Advances in Hematology, 2020, 11, 204062072095500.	2.5	19
80	A phase 1 dose escalation study of the <i>IDH1</i> m inhibitor, FT-2102, in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Journal of Clinical Oncology, 2018, 36, 7009-7009.	1.6	19
81	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 2010, 95, 892-899.	3.5	18
82	Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies. Leukemia, 2012, 26, 1686-1689.	7.2	18
83	Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Advances, 2021, 5, 994-1002.	5.2	18
84	Azacitidine treatment for patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 3q abnormalities. American Journal of Hematology, 2015, 90, 859-863.	4.1	17
85	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	1.3	17
86	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. Experimental Hematology, 2010, 38, 55-60.	0.4	16
87	Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone. Leukemia Research, 2011, 35, 80-86.	0.8	16
88	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. Leukemia Research, 2014, 38, 29-33.	0.8	16
89	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leukemia Research, 2014, 38, 1430-1434.	0.8	16
90	Prognostic significance of myelodysplasiaâ€related changes according to the <scp>WHO</scp> classification among <scp>ELN</scp> â€intermediateâ€risk <scp>AML</scp> patients. American Journal of Hematology, 2015, 90, E22-4.	4.1	16

#	Article	IF	CITATIONS
91	New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities. Expert Review of Hematology, 2016, 9, 377-388.	2.2	16
92	Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia and Lymphoma, 2017, 58, 982-985.	1.3	16
93	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study. Blood, 2018, 132, 1452-1452.	1.4	16
94	Incidence of <scp>ATRX</scp> mutations in myelodysplastic syndromes, the value of microcytosis. American Journal of Hematology, 2015, 90, 737-738.	4.1	15
95	An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. Oncotarget, 2016, 7, 51163-51173.	1.8	15
96	Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care. Blood Cancer Journal, 2017, 7, 644.	6.2	15
97	Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy. Oncotarget, 2017, 8, 81926-81935.	1.8	15
98	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leukemia and Lymphoma, 2017, 58, 1880-1886.	1.3	14
99	Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine. Leukemia Research, 2017, 63, 72-77.	0.8	14
100	Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia Journal of Clinical Oncology, 2019, 37, 7030-7030.	1.6	14
101	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 766-770.e4.	0.4	13
102	Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system. Haematologica, 2016, 101, e427-e428.	3.5	13
103	Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings. Expert Opinion on Pharmacotherapy, 2017, 18, 1213-1224.	1.8	13
104	Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leukemia and Lymphoma, 2013, 54, 1538-1540.	1.3	12
105	Poor Outcome with Nonmyeloablative Conditioning Regimen before Cord Blood Transplantation for Patients with High-Risk Acute Myeloid Leukemia Compared with Matched Related orÂUnrelated Donor Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1560-1565.	2.0	11
106	Trends in Clinical Investigation for Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, S57-S63.	0.4	11
107	Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). Blood, 2018, 132, 1453-1453.	1.4	11
108	In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2. Leukemia, 2022, 36, 1313-1323.	7.2	11

#	Article	IF	CITATIONS
109	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preâ€leukaemic clone resulting in T2―ALL and AML â€MO. Journal of Cellular and Molecular Medicine, 2017, 21, 1237-1242.	3.6	10
110	Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase <scp>II</scp> addâ€on study from the Groupe Francophone des Myelodysplasies. British Journal of Haematology, 2018, 180, 735-737.	2.5	10
111	Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy. Oncotarget, 2017, 8, 37866-37874.	1.8	10
112	Presence of a minor Philadelphia-positive clone in young adults withde novoT-cell ALL. Leukemia and Lymphoma, 2009, 50, 485-487.	1.3	9
113	Extensive chronic GVHD is associated with donor blood CD34+ cell count after G-CSF mobilization in non-myeloablative allogeneic PBSC transplantation. Bone Marrow Transplantation, 2012, 47, 1564-1568.	2.4	9
114	Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. Blood, 2010, 116, 601-601.	1.4	9
115	Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget, 2016, 7, 85937-85947.	1.8	9
116	PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia. Leukemia, 2015, 29, 1202-1206.	7.2	8
117	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). Blood, 2011, 118, 609-609.	1.4	8
118	Secondary Philadelphia chromosome after non-myeloablative peripheral blood stem cell transplantation for a myelodysplastic syndrome in transformation. Bone Marrow Transplantation, 2004, 33, 247-249.	2.4	7
119	Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction. Leukemia and Lymphoma, 2012, 53, 2186-2191.	1.3	7
120	Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2014, 55, 2211-2212.	1.3	7
121	A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes. The Hematology Journal, 2004, 5, 209-215.	1.4	7
122	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM). Blood, 2010, 116, 508-508.	1.4	7
123	Repeated Dosing Of Anti-KIR (IPH2101) As Maintenance Therapy In Ederly Patients With Acute Myeloid Leukemia. Blood, 2013, 122, 2696-2696.	1.4	7
124	Risk stratification in myelodysplastic syndromes: is there a role for gene expression profiling?. Expert Review of Hematology, 2014, 7, 191-194.	2.2	6
125	Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1754-1758.	2.0	6
126	Insights into novel emerging epigenetic drugs in myeloid malignancies. Therapeutic Advances in Hematology, 2019, 10, 204062071986608.	2.5	6

#	Article	IF	CITATIONS
127	Clinical evaluation of combined azacitidine and entinostat on the induction of fetal hemoglobin in patients with acute myeloid leukemias and myelodysplastic syndromes. Leukemia and Lymphoma, 2018, 59, 755-757.	1.3	6
128	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/â^' Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. Blood, 2010, 116, 1880-1880.	1.4	6
129	Impact Of Cytogenetics and Cytogenetic Response On Outcome In Myelodysplastic Syndromes (MDS) treated With Azacitidine (AZA). A Collaborative Study In 878 Patients. Blood, 2013, 122, 389-389.	1.4	6
130	Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal of Cutaneous Pathology, 2019, 46, 930-934.	1.3	5
131	High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia and Lymphoma, 2021, 62, 1195-1202.	1.3	5
132	A 10 Day Schedule of Azacitidine Induces More Complete Cytogenetic Remissions Than the Standard Schedule In Myelodysplasia and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the E1905 US Leukemia Intergroup Study. Blood, 2010, 116, 4013-4013.	1.4	5
133	The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort. Blood, 2016, 128, 1063-1063.	1.4	5
134	Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study. Blood, 2013, 122, 2777-2777.	1.4	5
135	A simplified, 96-well–adapted, ATP luminescence–based motility assay. BioTechniques, 2009, 47, 871-875.	1.8	4
136	Treatment of High Risk MDS and AML Post-MDS with Azacytidine (AZA): Preliminary Results of the French ATU Program Blood, 2006, 108, 2664-2664.	1.4	4
137	Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study Blood, 2009, 114, 1049-1049.	1.4	4
138	Natural Killer Cells Recovery After Consolidation Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML). Blood, 2011, 118, 2189-2189.	1.4	4
139	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138.	1.4	4
140	Autologous hematopoietic stem cell transplantation for adults with acute myeloid leukemia in complete remission: The Edouard Herriot hospital experience. Hematology, 2006, 11, 157-164.	1.5	3
141	Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?. Blood Reviews, 2016, 30, 381-388.	5.7	3
142	Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy. Blood, 2015, 126, 95-95.	1.4	3
143	Allogeneic hematopoietic SCT and mechanical heart valve: feasibility of reduced toxicity myeloablative conditioning. Bone Marrow Transplantation, 2010, 45, 1574-1575.	2.4	2
144	Treatment of Acute Promyelocytic Leukemia for Older Patients. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 337-342.	4.9	2

#	Article	IF	CITATIONS
145	Development of Epigenetic Targeted Therapies in Hematological Malignancies. , 2015, , 169-187.		2
146	Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals of Hematology, 2016, 95, 1895-1898.	1.8	2
147	What are the most promising new agents in myelodysplastic syndromes?. Current Opinion in Hematology, 2019, 26, 77-87.	2.5	2
148	Hypomethylating agent based combinations in higher risk myelodysplastic syndrome. Leukemia and Lymphoma, 2020, 61, 1012-1027.	1.3	2
149	Comprehensive Clinicopathologic and Molecular Analysis of Mast Cell Leukemia With Associated Hematologic Neoplasm: A Report and In-Depth Study of 5 Cases. Frontiers in Oncology, 2021, 11, 730503.	2.8	2
150	High Relapse Rate of Acute Myeloid Leukemia with Translocation (8;21) or Inversion (16) in Elderly Patients Treated with Conventional Chemotherapy Blood, 2007, 110, 4365-4365.	1.4	2
151	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). Blood, 2013, 122, 620-620.	1.4	2
152	Prognostic understanding in acute leukemia: Patient-physician differences Journal of Clinical Oncology, 2018, 36, e22124-e22124.	1.6	2
153	A Phase I-II Study of Vorinostat and Low Dose Cytarabine for Patients Treated for High Risk Myelodysplastic with Azacytidine Failure: The GFM-VOR2007 Study. Blood, 2010, 116, 4003-4003.	1.4	2
154	A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia and Lymphoma, 2022, , 1-9.	1.3	2
155	5-azacitidine in the treatment of myelodysplastic syndrome and acute myeloid leukemia. International Journal of Hematologic Oncology, 2013, 2, 419-428.	1.6	1
156	Impact of an automatic palliative care consultation trigger on healthcare use in patients with relapsed/refractory acute myeloid leukemia Journal of Clinical Oncology, 2021, 39, 224-224.	1.6	1
157	Impact of CRi on the Outcome of Elderly Patients with Acute Myeloid Leukemia Blood, 2007, 110, 4384-4384.	1.4	1
158	Azacitidine Treatment For Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Harboring Chromosome 3q Abnormalities. Blood, 2013, 122, 1512-1512.	1.4	1
159	Impact Of Anthracycline Dose Intensification On Minimal Residual Disease and Outcome Of Core Binding Factors Acute Myeloid Leukemias. Blood, 2013, 122, 2681-2681.	1.4	1
160	Prognostic Factors Of Response and Survival To Azacitidine (AZA) +/- EPO In RBC Transfusion Dependent (TD) IPSS Low and Int-1 (LR) MDS Resistant To EPO, With Particular Emphasis Of Genetic Lesions: A Study By The GFM. Blood, 2013, 122, 658-658.	1.4	1
161	Preventive Versus Curative Platelet Transfusion Strategies in the Treatment of Acute Myeloid Leukemia Patients: A Comparative Study. Blood, 2014, 124, 4288-4288.	1.4	1
162	Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress Blood, 2007, 110, 889-889.	1.4	1

#	Article	IF	CITATIONS
163	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism. Blood, 2013, 122, 2761-2761.	1.4	1
164	The PTK7 Receptor Family. , 2015, , 539-558.		1
165	French consensus on myelodysplasic syndrome and chronic myelomonocytic leukemia: diagnostic, classification and treatment 2015 update by the Myelodysplasia French Group. Hematologie, 2015, 21, 28-45.	0.0	1
166	Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood, 2015, 126, 3285-3285.	1.4	1
167	A Phase II Add-on Study of Vorinostat (VOR) in Higher Risk Myelodysplastic Syndrome with Failure of Hypomethylating Agents (HMA): The GFM Azavor Study. Blood, 2015, 126, 2900-2900.	1.4	1
168	Antifungal Prophylaxis in AML Patients Receiving Intensive Induction Chemotherapy. Prospective Observational Study from the Acute Leukemia French Association (ALFA) Group. Blood, 2016, 128, 3696-3696.	1.4	1
169	Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood, 2021, 138, 3018-3018.	1.4	1
170	P111 Long-term outcome of MDS with del 5q before the lenalidomide era. The GFM experience. Leukemia Research, 2009, 33, S124.	0.8	0
171	Clinical Applications of Epigenetic Drugs. , 2016, , 329-346.		0
172	Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2019, 60, 246-249.	1.3	0
173	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies Blood, 2007, 110, 901-901.	1.4	0
174	Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs). Blood, 2010, 116, 4002-4002.	1.4	0
175	Post-Transcriptional Deregulation of MYC Via PTEN Constitutes a Major Alternative Pathway of MYC Activation In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 4188-4188.	1.4	0
176	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. Blood, 2011, 118, 945-945.	1.4	0
177	Combination of Cytarabine and Topotecan Improves Response Rate for Patients Treated for Acute Myeloid Leukemia with Persistent Disease After Frontline Induction. Blood, 2011, 118, 2605-2605.	1.4	0
178	Fertility in Female Patients After Allogeneic Stem Cell Transplantation Following Reduced-Intensity Conditioning (RIC allo-SCT). Blood, 2011, 118, 3057-3057.	1.4	0
179	Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience. Blood, 2011, 118, 2623-2623.	1.4	0
180	Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 801-806.	1.7	0

#	Article	IF	CITATIONS
181	The Addition of ONE-Day Rest Between LAST ATG Infusion and STEM CELL Infusion DID NOT Affect Gvhd Occurrence After Allogeneic TRANSPLANTATION with Fludarabine-Busulfan-ATG Conditioning Blood, 2012, 120, 3029-3029.	1.4	0
182	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	1.4	0
183	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. Blood, 2012, 120, 1719-1719.	1.4	Ο
184	Reduced Intensity Conditioning Based On Fludarabine, Intravenous Busulfan (2 Days) and Antithymocyte Globulins (2 Days) Results In High Disease Free Survival Without Persisting Gvhd In Patients Transplanted For Hematological Malignancies: Large Single Center Cohort With Long Follow-Up. Blood, 2013, 122, 3364-3364.	1.4	0
185	H3K27me3 Level of the HIST1 Cluster Defines an Epigenetic Marker of Acute Myeloid Leukemia with Prognostic Value. Blood, 2014, 124, 2326-2326.	1.4	ο
186	Incidence of Atrx Mutations in Myelodysplastic Syndromes (MDS). Blood, 2014, 124, 4629-4629.	1.4	0
187	Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey. Blood, 2015, 126, 4455-4455.	1.4	0
188	Clinical Evaluation of Combined Epigenetic Therapies on the Induction of Fetal Hemoglobin in Patients with Hematologic Malignancies. Blood, 2015, 126, 960-960.	1.4	0
189	Evaluation of Salvage Induction Chemotherapy Regimens in Higher Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia after Hypomethylating Agent Treatment Failure. Blood, 2016, 128, 348-348.	1.4	0